San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, ADARx Pharmaceuticals is raising $15,499,998.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Zhen Li played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ADARx Pharmaceuticals

We are a messenger RNA base-editing company. Our mission is to discover and develop cutting-edge genetic therapeutics that precisely target and edit single point mutations on RNA transcripts to enable production of desired proteins. RNA editing is a process through which a nucleotide sequence specified in the genomic template is modified to produce a different nucleotide sequence in the transcript. By recruitment of endogenous ADARs, RNA editing therapeutics can precisely edit single point mutations, from A to G on messenger RNA to enable production of desired proteins. RNA editing therapeutics hold great promise to provide medicines for current undruggable diseases.

To learn more about ADARx Pharmaceuticals, visit http://www.adarx.com/

Contact:
Zhen Li, President and Chief Executive Officer
858-283-9472

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved